Your browser doesn't support javascript.
loading
Phase II Trial of Chemopreventive Effects of Levonorgestrel on Ovarian and Fallopian Tube Epithelium in Women at High Risk for Ovarian Cancer: An NRG Oncology Group/GOG Study.
Rodriguez, Gustavo C; Kauderer, James; Hunn, Jessica; Thaete, Larry G; Watkin, William G; Russell, Samantha; Yozwiak, Michael; Basil, Jack; Hurteau, Jean; Lele, Shashikant; Modesitt, Susan C; Zivanovic, Oliver; Zhang, Hao Helen; Bartels, Peter H; Alberts, David S.
Afiliación
  • Rodriguez GC; Division of Gynecologic Oncology, NorthShore University HealthSystem, Evanston, Illinois. grodriguez@northshore.org.
  • Kauderer J; Department of Obstetrics and Gynecology, University of Chicago, Chicago, Illinois.
  • Hunn J; NRG Oncology, Clinical trial Development Division, Biostatistics & Bioinformatics, Roswell Park Cancer Institute; Buffalo, New York.
  • Thaete LG; Division of Gynecologic Oncology, NorthShore University HealthSystem, Evanston, Illinois.
  • Watkin WG; Department of Obstetrics and Gynecology, University of Chicago, Chicago, Illinois.
  • Russell S; Division of Gynecologic Oncology, NorthShore University HealthSystem, Evanston, Illinois.
  • Yozwiak M; Department of Obstetrics and Gynecology, University of Chicago, Chicago, Illinois.
  • Basil J; Department of Pathology, NorthShore University Health System, Evanston, Illinois.
  • Hurteau J; Department of Pathology, University of Chicago Pritzker School of Medicine, Chicago, Illinois.
  • Lele S; Cancer Prevention and Control, University of Arizona Cancer Center, Phoenix, Arizona.
  • Modesitt SC; Cancer Prevention and Control, University of Arizona Cancer Center, Phoenix, Arizona.
  • Zivanovic O; TriHealth Hospitals, Cincinnati, Ohio.
  • Zhang HH; Division of Gynecologic Oncology, NorthShore University HealthSystem, Evanston, Illinois.
  • Bartels PH; Department of Obstetrics and Gynecology, University of Chicago, Chicago, Illinois.
  • Alberts DS; Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Cancer Prev Res (Phila) ; 12(6): 401-412, 2019 06.
Article en En | MEDLINE | ID: mdl-31015198
A large body of epidemiologic evidence has shown that use of progestin-containing preparations lowers ovarian cancer risk. The purpose of the current study was to gather further preclinical evidence supporting progestins as cancer chemopreventives by demonstrating progestin-activation of surrogate endpoint biomarkers pertinent to cancer prevention in the genital tract of women at increased risk of ovarian cancer. There were 64 women enrolled in a multi-institutional randomized trial who chose to undergo risk-reducing bilateral salpingo-oophorectomy (BSO) and to receive the progestin levonorgestrel or placebo for 4 to 6 weeks prior to undergoing BSO. The ovarian and fallopian tube epithelia (FTE) were compared immunohistochemically for effects of levonorgestrel on apoptosis (primary endpoint). Secondary endpoints included TGFß isoform expression, proliferation, and karyometric features of nuclear abnormality. In both the ovary and fallopian tube, levonorgestrel did not confer significant changes in apoptosis or expression of the TGFß1, 2, or 3 isoforms. In the ovarian epithelium, treatment with levonorgestrel significantly decreased the proliferation index. The mean ovarian Ki-67 value in the placebo arm was 2.027 per 100 cells versus 0.775 per 100 cells in the levonorgestrel arm (two-sided P value via Mann-Whitney U test = 0.0114). The karyometric signature of nuclei in both the ovarian and FTE deviated significantly from normal controls (women at average risk of ovarian cancer), but was significantly less abnormal in women treated with levonorgestrel. These karyometric data further support the idea that progestins may clear genetically abnormal cells and act as chemopreventive agents against ovarian and fallopian tube cancer.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Levonorgestrel / Neoplasias de las Trompas Uterinas / Agentes Anticonceptivos Hormonales Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Cancer Prev Res (Phila) Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Levonorgestrel / Neoplasias de las Trompas Uterinas / Agentes Anticonceptivos Hormonales Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Cancer Prev Res (Phila) Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos